Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Jack of All Trades who wrote (2797)	5/15/1998 3:19:00 PM
From: Steven Angelil	Respond to of 25711

I know, I just got screwed on my second order. Hit enter when the ask was 2 7/8 and I got filled at 3 3/16. Time to put in a dispute with Ameritrade, I think my order got delayed. Steve

To: Jack of All Trades who wrote (2797)	5/15/1998 3:19:00 PM
From: P.E. Allen	Read Replies (1) \| Respond to of 25711

They got technology and more: Tuesday April 7, 8:06 am Eastern Time Company Press Release NetMed Completes Successful Test of Ceramic Oxygen Generator Targets Commercialization Within 12 Months DUBLIN, Ohio--(BUSINESS WIRE)--April 7, 1998--NetMed, Inc. (AMEX: NMD - news), a developer and marketer of medical and health-related technologies, announced today that the company has successfully completed acceptance testing of a prototype of a ceramic oxygen generator which will be incorporated into its OxyNet(R) oxygen concentrator for the home healthcare market. The company also announced the closing of a previously announced transaction with CeramPhysics, Inc. wherein the company has acquired 95 percent of the CeramPhysics subsidiary which holds an exclusive worldwide license to the technology for all applications except fuel cells and oxygen sensors. The patented technology draws room air through a proprietary ceramic element to produce and collect pure oxygen. The technology has been in development for more than five years, partly with the assistance of NetMed. ''Our goal'', said David J. Richards, NetMed president and chief executive officer, ''is to produce and market an oxygen concentrator for home use that will be significantly better than products currently in the marketplace, which are based on 25-year-old technology. We believe this patented oxygen system will be lighter, quieter, more reliable and less costly to own than current systems, and we are committed to commercializing the technology within the next 12 months.'' Richards said that the company expects to demonstrate a 4 liter per minute commercial prototype of the system this summer and to begin marketing a 5-6 liter per minute device during the second quarter of 1999. Although the ceramic oxygen technology has many potential markets, including military and industrial uses, NetMed's initial focus will be to market the OxyNet home oxygen concentrator to home healthcare providers who provide medical equipment directly to both patients and health care organizations such as hospitals and nursing homes. ''Our immediate goal is to capitalize on the opportunity in the home oxygen market,'' said Mr. Richards, ''However we think the technology provides many significant long term opportunities in related markets.'' The annual worldwide market for oxygen concentrators is estimated at close to $300 million, according to Richards, and is expected to grow at an annual rate of 10 to 12 percent per year over the next several years. Statements in this release which relate to other than strictly historical facts, including statements about the Company's plans and strategies, as well as management's expectations about new and existing products, technologies and opportunities, market growth, demand for and acceptance of new and existing products (including the PAPNET Testing System and the OxyNet oxygen concentration device), are forward looking statements. The words ''believe,'' ''expect,'' ''anticipate,'' ''estimate,'' ''project,'' and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's current reliance on a single product marketed under license from NSI, the corresponding dependence on NSI's patents and proprietary technology, government regulation, continuing losses from operations and negative cash flow, limited marketing and sales history, the impact of third party reimbursement decisions, the challenges of research and development of new products, and other risks detailed in the Company's most recent annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. Contact: NetMed, Inc. Ken Leachman Vice President, Finance (614) 793-9356 or Porter, LeVay & Rose, Inc. Martin Skala, Vice President John Chuhran, Media Consultant 212/564-4700 More Quotes and News: Netmed Inc (AMEX:NMD - news) Related News Categories: biotech, medical/pharmaceutical